Latest Articles & Insights

Stay informed with the latest pharmaceutical regulations, industry insights, and expert guidance from our team of licensed pharmacists.

Registration

April 5, 2026

Proactive Regulatory Engagement and ISO Certification for AI-Powered Digital Mental Health Companion Platform

Early regulatory engagement with the FDA, combined with ISO 13485-certified quality management systems, 16 clinical trials involving over 1,800 participants, and real-world deployment experience enabled the development of fully automated AI-powered digital companions that deliver personalized, evidence-based chat-based support for anxiety and depression symptoms, broadening product offerings across adults, adolescents, and maternal health while exploring novel pathways from general wellness to potential FDA-cleared solutions to address surging mental health needs and provider shortages.

Registration

April 5, 2026

Pioneering Interoperable Automated Insulin Delivery System Clearance Through FDA Expedited Component Pathway

Early FDA engagement on an expedited interoperable pathway for automated insulin delivery components enabled the first fully interoperable closed-loop automated insulin dosing app to achieve 510(k) clearance, transforming patient-led DIY innovation into a regulated solution that integrates independently reviewed continuous glucose monitors and pumps, providing greater choice for individuals with insulin-dependent diabetes while addressing safety concerns and streamlining future submissions as a predicate device.

Registration

April 5, 2026

Proactive FDA Engagement for 510(k) Clearance of AI-Powered 3D Digital Breast Tomosynthesis Analysis Software

Early regulatory intelligence combined with proactive pre-submission engagement with the FDA, informed by prior lessons from mammography AI submissions, enabled the development and swift 510(k) clearance of an advanced AI algorithm designed to analyze 3D images generated by digital breast tomosynthesis equipment, delivering faster and more accurate breast cancer detection compared with conventional 2D mammography while meeting rigorous standards for accuracy, reliability, and repeatability.

Registration

April 4, 2026

FDA Pre-Submission Engagement and Service-Based Reimbursement Model for EMG Biofeedback Digital Therapy Platform

Early FDA engagement and recognition of neuromuscular re-education as a reimbursable clinical service enabled 510(k) exempt status and breakthrough device designation for EMG-based therapies, facilitating EHR integration for direct prescription retrieval, reimbursement under four CPT codes and remote therapeutic monitoring codes, and deployment across health systems, ambulatory clinics, and home settings for conditions including stroke, chronic pain, pelvic health, and movement disorders.

Registration

April 4, 2026

Pre-Submission FDA Engagement for 510(k) Clearance of Pediatric Wearable Remote Monitoring Platform

Early and iterative pre-submission meetings with the FDA enabled the development and 510(k) clearance of a miniaturized wearable monitoring bracelet and cloud-based analytics platform for out-of-hospital monitoring of newborns and children, addressing unique pediatric anatomical and physiological differences through US-specific clinical testing, gap analysis versus European data, and an exempt user fee, resulting in market access for remote physiologic monitoring and predictive health assessment to reduce hospitalizations.

Registration

April 4, 2026

Early FDA Engagement Strategy for 510(k) Clearance of Multifunctional Wearable Digital Health Monitoring Platform

Early and iterative pre-submission engagement with multiple FDA review divisions enabled the successful development and 510(k) clearance of a full-stack, condition-agnostic digital health monitoring platform, supporting integration with third-party algorithms, remote physiologic monitoring in home-healthcare settings for individuals aged 18 and older, and validation of over 100 digital clinical measurements for research and clinical care.

Registration

April 4, 2026

Navigating the US Medical Device Clinical Trial Landscape: FDA Rules Study Design and Best Practices

A complete practical roadmap for medical device sponsors covering FDA risk-based classification, IDE versus IRB pathways, tailored study design, site selection benchmarks, recruitment and retention strategies, remote monitoring implementation, change control processes, and how to leverage international data for faster US market entry while meeting all compliance requirements.

Podcast

April 3, 2026

Navigating the Indonesian Regulatory Landscape: An Interview with Hussein Haidar

In this episode of The Elendi Files, Hussein Haidar, CEO of Product Registration Indonesia, breaks down the 'obligatory favoritism' of local content (TKDN), the risks of exclusive distributorship, and the evolving Halal requirements for medical devices.

Registration

April 3, 2026

Establishing Pharmaceutical-Grade Evidence for Novel Prescription Digital Therapeutics in Major Depressive Disorder

By engaging the FDA through pre-submission meetings and mirroring pharmaceutical-level evidence requirements, the regulatory pathway for a novel software-based prescription digital therapeutic overcame payer skepticism regarding shorter development timelines and different safety-efficacy standards, secured 510(k) clearance tailored to its distinctive cognitive-emotional capabilities for major depressive disorder, demonstrated no treatment-related adverse events when paired with antidepressant medication, and achieved strong psychiatrist endorsement that exclusive brain training improves outcomes beyond cognitive behavioral therapy alone.